Cello Group (CLL) Given “Buy” Rating at FinnCap
Separately, N+1 Singer reissued a buy rating and set a GBX 131 ($1.76) price target on shares of Cello Group in a research report on Wednesday, September 20th.
Shares of Cello Group (LON:CLL) remained flat at $GBX 126 ($1.70) during midday trading on Monday. 17,881 shares of the company’s stock were exchanged, compared to its average volume of 37,703. Cello Group has a 12-month low of GBX 95.20 ($1.28) and a 12-month high of GBX 140 ($1.88).
In other news, insider Mark Bentley purchased 110,000 shares of the stock in a transaction on Wednesday, September 27th. The stock was purchased at an average price of GBX 128 ($1.72) per share, with a total value of £140,800 ($189,502.02).
About Cello Group
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with Analyst Ratings Network's FREE daily email newsletter.